Related Experiment Video
Updated: Aug 5, 2025
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
Published on: November 17, 2018
Current Trends in Neoantigen-Based Cancer Vaccines
Szu-Ying Ho1, Che-Mai Chang1, Hsin-Ni Liao1
1Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei City 110, Taiwan.
Abstract:
Cancer immunotherapies are treatments that use drugs or cells to activate patients' own immune systems against cancer cells. Among them, cancer vaccines have recently been rapidly developed. Based on tumor-specific antigens referred to as neoantigens, these vaccines can be in various forms such as messenger (m)RNA and synthetic peptides to activate cytotoxic T cells and act with or without dendritic cells. Growing evidence suggests that neoantigen-based cancer vaccines possess a very promising future, yet the processes of immune recognition and activation to relay identification of a neoantigen through the histocompatibility complex (MHC) and T-cell receptor (TCR) remain unclear. Here, we describe features of neoantigens and the biological process of validating neoantigens, along with a discussion of recent progress in the scientific development and clinical applications of neoantigen-based cancer vaccines.
Insights
Neoantigen-based cancer vaccines show promise by activating the immune system against tumors. Further research is needed to clarify the precise mechanisms of immune recognition and activation for these advanced therapies.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Cancer immunotherapies leverage the patient's immune system to combat cancer.
- Neoantigens, or tumor-specific antigens, are key targets for novel cancer vaccines.
- Current neoantigen-based vaccines utilize mRNA or synthetic peptides to stimulate immune responses.
Purpose of the Study:
- To describe the characteristics and validation processes of neoantigens.
- To review the scientific development of neoantigen-based cancer vaccines.
- To discuss the clinical applications and future potential of these vaccines.
Main Methods:
- Review of scientific literature on neoantigens and cancer vaccines.
- Analysis of the biological processes involved in neoantigen recognition (MHC-TCR interactions).
- Discussion of recent advancements in vaccine platforms and clinical trials.
Main Results:
- Neoantigens are crucial for targeted cancer immunotherapy.
- Various vaccine platforms (mRNA, peptide) are being developed.
- Understanding MHC-TCR interactions is vital for optimizing vaccine efficacy.
Conclusions:
- Neoantigen-based cancer vaccines represent a promising therapeutic strategy.
- Further elucidation of immune recognition pathways is necessary.
- Continued research and clinical trials are essential for advancing this field.
More Related Videos
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...